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Loss of the cyclin-dependent kinase inhibitor p27Kip1 leads to an
overall increase in animal growth, pituitary tumors, and hyperpla-
sia of hematopoietic organs, yet it is unknown whether all cells
function autonomously in response to p27Kip1 activity or whether
certain cells take cues from their neighbors. In addition, there is
currently no genetic evidence that tumor suppression by p27Kip1 is
cell-autonomous because biallelic gene inactivation is absent from
tumors arising in p27Kip1 hemizygous mice. We have addressed
these questions with tissue-specific targeted mouse mutants and
radiation chimeras. Our results indicate that the suppression of
pars intermedia pituitary tumors by p27Kip1 is cell-autonomous and
does not contribute to overgrowth or infertility phenotypes. In
contrast, suppression of spleen growth and hematopoietic pro-
genitor expansion is a consequence of p27Kip1 function external to
the hematopoietic compartment. Likewise, p27Kip1 suppresses thy-
mocyte hyperplasia through a cell-nonautonomous mechanism.
The interaction of p27Kip1 loss with epithelial cell-specific cyclin-
dependent kinase 4 overexpression identifies the thymic epithe-
lium as a relevant site of p27Kip1 activity for the regulation of
thymus growth.
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In the mouse, loss of the p27Kip1 cyclin-dependent kinase (CDK)inhibitor induces increased growth of the whole animal, tumors
of the pituitary intermediate lobe (pars intermedia), and a dispro-
portionate degree of hyperplasia of the thymus and spleen (1–3). A
similar phenotype is observed with disruption of p18Ink4c, a CDK
inhibitor specific for the D-type cyclins (4). Because these molecules
modify the intracellular activity of CDKs, it is commonly presumed
that their mechanism of growth control is chiefly cell-autonomous.
However, it is not known how loss of these inhibitors causes
proportionate growth in some tissues but not in others. One
hypothesis is that loss of p27Kip1 alters an internal counting mech-
anism of cells and thus all tissues undergo additional cell divisions
during their growth phase and then exit from the cell cycle (5).
However, not all cell lineages contribute equally to the growth
process. In hematopoietic tissues, for example, loss of p27Kip1 causes
disproportionate expansion of hematopoietic progenitors and stem
cells (6–8). Lymphocytes display increased in vitro sensitivity to
IL-2 and other cytokines (1, 9).
Alternatively, loss of CDK inhibitors could alter growth by
cell-nonautonomous mechanisms such as an endocrine disturbance.
The fact that p27Kip1 knockout mice develop pituitary tumors raised
suspicion that hormone alterations could account for the growth
and female infertility phenotypes. Growth hormone or IGF-1 also
causes hyperplasia of the thymus relative to other organs (10). Yet
marked differences in growth hormone, IGF-1, and IGF-2 were not
seen in p27Kip1 knockout mice (1, 2). In addition, spontaneous
tumors arise chief ly in -melanocyte-stimulating hormone-
producing melanotroph cells, not in growth hormone and gonado-
tropin-producing cells of the adjacent pars distalis (homologue of
the human anterior lobe). It is possible that -melanocyte-
stimulating hormone contributes to infertility considering that,
administered exogenously, it alters estrous cycle of rats and de-
creases progesterone production of ovarian granulosa cells (11).
Other forms of cell-nonautonomous mechanisms of growth control
include local production of paracrine factors and cellular contact.
For example, forced expression of cyclin D1 in the thymic epithelial
cells with the keratin 5 (K5) promoter leads to marked thymic
lymphocyte hyperplasia and overgrowth of the entire organ (12). It
is conceivable that spleen and thymus hyperplasia induced by loss
of p27Kip1 is also due to its loss of function outside of the hema-
topoietic cell compartment.
In addition to these developmental phenotypes, there is reason
to question whether tumor suppression by p27Kip1 is cell-
autonomous. Hemizygous p27/ mice develop tumors of the pars
intermedia and other tissues after -irradiation (6). However,
unlike the classic tumor suppressor gene Rb, whose loss also causes
tumors in the pars intermedia, tumors arising in mice lacking one
copy of p27Kip1 or p18Ink4c do not acquire bialleleic gene mutations
(6, 13). Thus, there is genetic evidence that tumor suppression by
p27Kip1 is haploinsufficient but no evidence that it is cell-
autonomous. Cell-nonautonomous mechanisms of tumor suppres-
sion include intracellular altered immune response, paracrine fac-
tors, and the suppression of angiogenesis. Our studies indicate that,
depending on the context, p27Kip1 suppresses growth by both
cell-autonomous and cell-nonautonomous mechanisms.
Results
p27loxP and p27stop Mouse Models. We have produced two types of
Cre-inducible targeted mutations of p27Kip1. The first strain,
p27loxP, harbors the (L) mutation with loxP sites flanking p27Kip1
(Fig. 1A). The introduction of the Cre recombinase into p27loxP
mice deletes the entire coding region of p27Kip1 and produces a null
allele (L). The second mouse model, p27stop, is a mouse strain
carrying a ‘‘Cre-on’’ targeted mutation of p27Kip1. A transcriptional
STOP cassette, which is flanked by loxP sites, was targeted to a
critical region of the p27Kip1 5 UTR, thereby producing a null allele
(S). However, the STOP cassette can be excised by Cre, resulting
in an activated allele (S) that expresses wild-type p27Kip1 under
control of its endogenous promoter (Fig. 1B).
Baseline Characteristics of p27loxP and p27stop Mice. We validated
the new p27Kip1 mutations by comparing uninduced mutants
(p27L/L and p27S/S) versus germ-line Cre-induced alleles
(p27L/L and p27S/S). As predicted, p27Kip1 protein is present
in p27L/L mice and is undetectable after Cre-mediated excision
in the p27L/L animals (Fig. 2A). Unexpectedly, quantitative
Western blots of p27L/L tissues showed a moderate reduction of
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p27Kip1 protein (Fig. 2B) and RNA levels (Fig. 7, which is published
as supporting information on the PNAS web site). Expression of
p27Kip1 is nearly undetectable in p27S/S mice, whereas p27Kip1
levels are normal in mice with the reactivated p27stop mutation
(p27S/S). Uninduced and constitutively induced p27loxP and
p27stop mice displayed the expected size (Fig. 2C) and organ
hyperplasia phenotypes (data not shown). However, uninduced
p27L/L mice demonstrated increased growth rates that were
intermediate between that of wild-type and constitutive knockouts,
consistent with their reduced protein expression.
Pituitary Gene Mutation by POMC–Cre in p27loxP and p27stop Mice.
To create pars intermedia pituitary-specific gene mutations, we
generated POMC–Cre transgenics that express the Cre recombi-
nase by the proopiomelanocortin (POMC) promoter (Fig. 1C). The
specificity of Cre was initially assessed by X-gal-staining tissues
from POMC–Cre transgenics bred to Rosa26 reporter mice
(R26R). Two founder lines showed the expected pattern for the
POMC promoter, i.e., a high level of -gal activity in the pituitary
pars intermedia, patchy activity in the pituitary pars distalis, and no
activity in other organs (Fig. 1 D–F). POMC–Cre transgenics were
then bred to both p27loxP and p27stop mouse strains. In tissues
where POMC–Cre should not be expressed deletion of the p27Kip1
gene was not detectable by PCR (Fig. 3A). Likewise, deletion of the
STOP cassette was always detectable in the pars intermedia of
p27stop mice carrying POMC–Cre (Fig. 3B). Quantitative Western
blots of pituitaries from p27L/L;POMC–Cre animals demon-
strate loss of p27Kip1 expression in the pars intermedia compared
with wild-type pituitaries (Fig. 3C), becoming complete between 6
and 15 weeks of age. Likewise, POMC–Cre restored expression of
p27Kip1 protein in p27S/S pituitary pars intermedia at 6 weeks, but
it did not further increase with time. The fact that the restoration
of p27 is only partial at 6 weeks of age is partly because of the
presence of pars nervosa or other POMC-negative cells in the tissue
preps. For males and females, the growth curves of mice carrying
POMC–Cre is nearly identical to the curves of mice without this
transgene. In other words, deletion of p27Kip1 from the pars
intermedia of p27loxP mice did not increase animal growth, and
restricting p27Kip1 expression to the pars intermedia in p27stop mice
did not suppress the overgrowth phenotype. Likewise, the presence
of POMC–Cre did not diminish fertility of p27loxP females, nor did
it restore fertility to p27stop females (see Table 1, which is published
as supporting information on the PNAS web site).
Autonomy of Pars Intermedia Pituitary Tumors. We assayed pituitary
tumor development to determine whether it requires mutation of
p27Kip1 outside the pars intermedia melanotrophs. p27loxP
(p27L/L) mice did not develop pituitary tumors (Fig. 4 A, E, and
F) in the absence of Cre. However, p27L/L;POMC–Cre mice
developed tumors of a size and appearance similar to those seen in
constitutive (p27L/L) null animals (Fig. 4 B and E). Thus, deletion
of p27Kip1 in the pituitary melanotroph cell is necessary and
sufficient for tumor development. In contrast, p27stop mice
(p27S/S) developed pituitary tumors similar in size to those of
constitutive null animals (Fig. 4 C and E) in the absence of Cre.
Activation of p27Kip1 with POMC–Cre in these mice (Fig. 4 D and
E) inhibited tumor development and prolonged their survival (Fig.
4G). Before 1 year of age, 32% of mice succumbed to nonmalignant
skin ulcers, but only two mice had large (15 mg) pituitary tumors
(Table 2, which is published as supporting information on the PNAS
web site). Southern blots and quantitative PCR (data not shown),
using these two pituitary tumors, demonstrated retention of the
p27(S) allele, indicating that they had arisen from a subset of cells
that failed to undergo POMC–Cre-mediated p27Kip1 reactivation.
In comparison to normal pars intermedia tissue, cyclin A-associated
kinase activity was modestly increased in tumor tissue (2.5-fold,
similar to other normal organs), yet not nearly as much as p27Kip1
knockout thymus (Fig. 3D).
Nonautonomous Spleen and Thymus Hyperplasia in Radiation Chime-
ras. We transplanted marrow from either wild-type or p27/ mice
into lethally irradiated knockout and wild-type recipients (Fig. 5A)
Fig. 2. Baseline assessments of p27loxP and p27stop mouse models. (A)
Western blot using fluorescent antibodies to p27 and -tubulin from extracts.
(B) Quantification of p27 protein levels in various tissues relative to that of
wild-type littermates of mice with constitutive p27loxP and p27stop muta-
tions (mean  SEM). Tissues from p27L/L mice show a significant decrease in
p27 protein relative to wild type (n  8, P  0.00015, Wilcoxon test). p27L/L
(n  4) and p27S/S (n  4) tissues do not show appreciable expression of p27.
(C) Growth curves. p27S/S mice are significantly larger than wild-type (WT)
and p27S/S mice and are comparable to constitutive p27L/L knockouts.
p27L/L mice show intermediate growth rates.
Fig. 1. p27loxP and p27stop targeted mutations and POMC–Cre transgenics
( and  designate the presence and absence of p27Kip1 expression from each
allele). (A) Schematic of p27LoxP mutations. The NL allele is preliminary the
result of targeting with the pKNFL vector. It includes two loxP sites (left
triangle) and Neo flanked by FRT sites (right triangle). The p27loxP mouse
carries the L allele with a pair of LoxP sites flanking p27Kip1. Cre recombinase
activity results in the L null allele. (B) p27stop mice harbor the S null allele,
which contains a Neo-STOP cassette in the 5 UTR (shaded) of p27Kip1. Cre
recombinase deletes the STOP cassette, resulting in the active S allele. (C)
Structure of the POMC–Cre transgene. X-Gal-stained pituitaries show the
location of Cre recombinase activity from POMC–Cre  R26R mice (D) com-
pared with R26-positive controls (E) and wild-type controls (F).








to test whether p27Kip1 suppresses hematopoietic cell growth by a
cell-autonomous mechanism. Recipients received transplants at 3
weeks of age, before the pubertal growth phase, and were necrop-
sied after full donor engraftment, 4–5 weeks later. Flow cytometry
using CD45 cell surface markers, which distinguished donor from
recipient hematopoietic cells, confirmed that the recipients had
achieved 98% donor chimerism. The spleens of p27/ recipient
animals were enlarged and hypercellular compared with p27/
recipients, regardless of the genotype of the donor cells with which
they had been transplanted (Fig. 5B). In addition, the spleens of
p27/ recipients harbored increased proportions of hematopoietic
progenitor cells, even if reconstituted with p27/ hematopoietic
cells (Fig. 5C). This result indicates that loss of p27Kip1 causes
expansion of hematopoietic progenitors by a mechanism involving
cells outside the hematopoietic cell compartment.
Thymuses of p27/ recipient animals were hyperplastic com-
pared with wild-type recipients regardless of the genotype of the
transplanted hematopoietic cells (Fig. 5D). The presence or ab-
sence of p27 protein in the thymuses was a function of the genotype
of the donor mice, which is expected because lymphocytes are the
predominant cell type in this organ. In addition, both cyclin A (Fig.
5E) and Cdk2-associated histone H1 kinase activity are increased
in the mice transplanted with p27/ donor cells. Flow cytometry
of transplanted animals demonstrated that all four groups had
similar profiles of lymphocyte differentiation as determined by
CD3, CD4, and CD8 subsets (data not shown). However, mice that
received p27/ donor marrow had a 2-fold relative increase in cells
harboring the  T cell receptor (Fig. 5F), which others have
shown to be characteristic of p27Kip1 knockout mice (14).
It has been reported that the K5 promoter is active in the thymic
epithelium and that forced expression of cyclin D1 by the K5
promoter causes marked thymus hyperplasia. However, the thymic
lymphocyte expansion was cell-nonautonomous because cyclin D
was not overexpressed in T cells (12). To determine whether forced
expression of Cdk4, a catalytic partner of cyclin D1, has a similar
effect, we assessed thymuses of K5–Cdk4 transgenic mice (15).
Western blots for Cdk4 (Fig. 6A) indicate that it is overexpressed
in thymic stromal tissues but not in thymocyte suspensions. How-
ever, unlike K5–cyclin D1 or K5–cyclin D2 transgenics, K5–Cdk4
mice did not develop progressive thymus hyperplasia (Fig. 6B) (12,
16). This finding is consistent with the hypothesis that cyclin D is
limiting in the thymic epithelium and that forced expression of Cdk4
in this tissue is not sufficient to induce organ hyperplasia. To test the
hypothesis that p27Kip1 loss cooperates with overexpression of Cdk4
in the thymic epithelium, we bred K5–Cdk4 mice to p27Kip1
knockouts. Remarkably, p27/;K5–Cdk4 compound mutant an-
Fig. 3. Effects of POMC–Cre expression in p27loxP and p27stop mice. (A) PCR
of tissues from p27L/L;POMC–Cre mice for the uninduced (L) and induced
(L) null version of the p27loxP allele. (B) PCR of similar tissues from a
p27S/S;POMC–Cre mouse for the uninduced null (S) and activated (S)
alleles. (C) Mean levels of p27Kip1 protein in the pituitary pars intermedia of
p27L/L (L) and p27S/S (S) (all POMC-Cre) mice plotted relative to wild
type is shown for mice at 6, 15, and 30 weeks of age (n  6 SEM). (D) Cyclin
A-associated histone H1 kinase activity (HH1) from pooled wild-type (WT) pars
intermedia tissue and individual pars intermedia tumors arising in p27L/L,
p27L/L;POMC–Cre, and p27S/S mice is shown in comparison to thymus
extracts. (E) Growth of p27/ and p27S/S mice is shown both with (Cre) and
without (Cre) POMC–Cre. (F) Growth curves of p27L/L mice compared with
p27L/L;POMC–Cre mice.
Fig. 4. Pituitary tumors and overall animal survival. In situ appearance of
pituitaries from p27L/L (A) and p27L/L;POMC–Cre (B) mice shows that
POMC–Cre induces pituitary tumor formation. (C) In contrast, p27S/S mice
develop spontaneous tumors. (D) POMC–Cre largely suppressed tumors in
p27stop mice, but some p27S/S. POMC–Cre mice developed smaller tumors
at 1 year of age. (E) Box plot of pars intermedia weights at 1 year of age or
when morbid. Median values (horizontal bar) are plotted with the first and
third quartiles (box), ranges (whiskers), and outliers (circles). (F) Percent
survival of p27L/L mice with POMC–Cre is shortened compared with p27L/L
mice without Cre (P  3  105, log-rank test) and is shown in comparison to
p27L/L and p27/;POMC–Cre controls. (G) Survival of p27S/S;POMC–Cre
mice is significantly prolonged compared with p27S/S mice without Cre (P 
3  1016) and is shown in comparison with mice with constitutively reacti-
vated allele (p27S/S) and wild-type p27 (WT).
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imals developed massive thymic hyperplasia (Fig. 6D). p27/;K5–
Cdk4 thymuses weighed 745  280 mg (mean  range) by day 100,
which is 4-fold larger than p27/ and 6-fold larger than Cdk4/
mice. Histological sections from these animals demonstrated nor-
mal thymocyte cell density but a marked increase in thymic
lymphocyte cellularity. Areas of medullary and cortical maturation
were present (Fig. 6G), and thymic expansion did not occur because
of infiltration by monomorphic lymphoblasts. Flow cytometry (data
not shown) showed normal proportions of CD4CD8 subsets in
p27-null mice with or without K5–Cdk4, and K5–Cdk4 did not lead
to further increases of  T cells.
Discussion
We analyzed genetic mosaic mouse models generated through
Cre-Lox technology and through stem cell transplantation and
show that, depending on the tissue type, p27Kip1 regulates growth
by both cell-autonomous and cell-nonautonomous mechanisms.
Our results support the model of a cell-autonomous mechanism of
tumor suppression in the pituitary. p27loxP mice developed a high
incidence of fatal tumors after tissue-specific deletion of the gene
in the pituitary pars intermedia. This finding shows that p27Kip1 is
required in the melanotroph cell itself for tumor suppressor func-
tion. In a corollary set of experiments, expression of p27Kip1
expression in the pars intermedia of p27stop mice suppressed
pituitary tumor development but did not prevent the mice from
developing skin ulcers. Despite an outwardly normal appearance,
two p27S/S;POMC–Cre mice had tumors of 15 mg at the time
of necropsy. However, these tumors arose in a subset of mela-
notroph cells that had failed to excise the Stop cassette. This finding
implies that p27Kip1-deficient melanotroph cells are capable of
forming tumors even when surrounded by melanotroph cells with
normal p27Kip1 expression. We conclude that loss of p27Kip1 ex-
pression outside of the pars intermedia is not sufficient to induce
pituitary tumors and that tumor suppression by p27Kip1 may be
autonomous at the level of individual melanotroph cells. Others
have demonstrated increased rates of pituitary tumor development
in mice lacking both p27Kip1 and either p18Ink4c or one copy of Rb
(4, 17, 18). We show that, despite the propensity to develop
spontaneous tumors, loss of p27Kip1 in the pars intermedia does not
induce extraordinary increases in cyclin ACdk2 kinase activity.
This finding is consistent with the hypothesis that this tissue is more
sensitive to modest changes in cyclinCdk activity or that its
mechanism of tumor suppression is independent of Cdk activity.
Although loss of p27Kip1 from POMC-producing cells was suf-
ficient to induce pituitary tumors in p27L/L;POMC–Cre mice,
it had no discernable effect on female fertility. This finding indicates
that loss of p27Kip1 from cells outside the pars intermedia is required
for the expression of this phenotype. In contrast, p27stop females
(p27S/S) rarely produced viable offspring. It is possible that
low-level p27Kip1 protein expression exists in certain cells in the
p27stop animals. However, tissue-specific expression of p27Kip1
expression in the pars intermedia (of p27S/S;POMC–Cre mice)
did not improve breeder productivity, so the pars intermedia does
not appear to play a significant role in the fertility defect. Similar
to female fertility, loss or gain of p27Kip1 expression in the pars
intermedia had no discernable effect on the overall animal growth
in the p27loxP and p27stop models. These data indicate that p27Kip1
gene disruption in the pars intermedia pituitary is sufficient to
induce tumors but does not cause overgrowth or infertility. How-
ever, this finding does not rule out functional defects in other
pituitary cell types such as the gonadotropin or growth hormone-
producing cells of the pars distalis. Indeed, p27Kip1;p18Ink4c double
knockouts demonstrate increased pars distalis proliferation in
Fig. 5. Cell-nonautonomous growth of the spleen and thymus. (A) p27/
bone marrow was transplanted into lethally irradiated p27/ (W3W) and
p27/ (W3K) recipients. Also, p27/ marrow was transplanted into p27/
(K3W) and p27/ (K3K) mice. Donor vs. recipient cells were distinguished
by flow cytometry with CD45 cell-surface markers. W, wild type; K, knockout.
(B) The spleens of p27/ recipient mice are heavier and hypercellular com-
pared with wild-type recipients. (C) p27/ recipient mice have increased
numbers of hematopoietic progenitor cells including CFC-GM, CFC-E, and
BFU-E compared with wild-type recipients. (D) p27/ recipient mice also
develop heavier thymuses with increased lymphocytes compared to p27/
recipients. (E) p27Kip1 protein is abundant in thymuses of mice transplanted
from p27/ donors. Cyclin A and Cdk2-associated histone H1 (HH1) kinase
activity is increased in thymuses from p27/ donors, but cyclin A levels are
unchanged. (F) Flow cytometry demonstrates that mice receiving transplants
from p27/ donors have a relative increase in  T cells.
Fig. 6. Cooperation of K5–Cdk4 and p27 deletion in thymic hyperplasia. (A)
Western blots show increased Cdk4 protein expression in thymic stroma but
not in thymocytes from K5–Cdk4 transgenics compared with wild-type con-
trols, with actin immunostaining as a loading control. (B–D) Appearance of the
thymus at 10 weeks in mice with p27Kip1 deletion (B), the K5–Cdk4 transgene
(C), or both p27Kip1 deletion and K5–Cdk4 (D). (E–G) Hematoxylin and eosin-
stained sections of 7-week-old thymuses show both medullary and cortical
thymic maturation in p27/ mice (E), K5–Cdk4 transgenics (F), and com-
pound p27/;K5–Cdk4 mutants (G).








response to growth hormone-releasing hormone administration,
and ovary transplants suggest that female infertility in p27Kip1-
deficient mice is due to a combination of ovarian and pituitary
defects (19, 20). Our p27loxP and p27stop mouse models in
combination with other cell-type-specific Cre transgenes may be
useful to determine whether other pituitary cells contribute to these
phenotypes.
In contrast to the pituitary, we found that p27Kip1 suppresses
hyperplasia of hematopoietic cells of the thymus and spleen by a
cell-nonautonomous mechanism. In radiation chimeras, thymus
and spleen overgrowth occurred in only p27/ recipient animals,
but it was not affected by the genotype of the donor cells. Likewise,
expansion of hematopoietic progenitors occurred by a cell-
nonautonomous mechanism, but we have not identified the cells
responsible for this phenotype. We examined cyclinCDK activity
from the thymuses of radiation chimeras because p27/ mice
display the most dramatic increase in cyclinCDK activity in this
tissue, perhaps because of a lack of compensatory function of
p21Cip1 (21). Interestingly, p27/ lymphocytes continue to display
marked increases in cyclin A and Cdk2 kinase activity even if
transplanted into wild-type recipients. These data indicate that loss
of p27Kip1 within thymocytes is sufficient to activate cyclinCDK
complexes but does not account for the overgrowth of the organ.
The fact that loss of p27Kip1 increases thymic lymphocyte numbers
by a cell-nonautonomous mechanism does not mean that p27Kip1
has no direct effects in T cells. In fact, we observed increased 
T cells in wild-type mice transplanted p27/ T cells, as reported
previously in untransplanted p27/ mice, implying that p27Kip1
directly increases the proportions of these cells (14). In addition, a
number of studies have shown enhanced responsiveness of p27/
T lymphocytes to in vitro stimulation (1, 9, 22). Thus it appears that
p27Kip1 expression within the lymphocyte itself controls the re-
sponse of T cells to IL-2 and other proliferative stimuli but does not
determine homeostatic thymocyte cell number.
Tissue-specific deletion of p27Kip1 in other cell types may be
necessary to positively identify the cells that drive thymic hyper-
plasia. However, our data from K5–Cdk4 transgenics strongly
suggest that the thymic epithelium is responsible. Although K5–
Cdk4 transgenics themselves have only minimal thymic enlarge-
ment, the combination of p27Kip1 deletion and K5–Cdk4 expression
has a dramatic synergistic effect on thymus size and cellularity.
Because the K5 promoter is active in the thymic epithelium but not
in thymocytes, it is likely that p27Kip1 interacts directly with cyclin
DCdk4 complexes in this cell type. The thymic epithelium plays an
essential role in thymus development and T cell maturation. It
mediates thymocyte responses to both local and systemic factors
such as IFN, androgen, and keratinocyte growth factor (23, 24).
The thymic epithelium, in turn, produces cytokines such as IL-7,
which regulates growth and differentiation of CD4CD8 thymo-
cytes (25). A similar mechanism may mediate the response to
p27Kip1 deficiency. It is also possible that p27Kip1 loss in the thymic
epithelium causes thymocyte expansion by interacting with mole-
cules other than cyclin DCdk4. For example, p27Kip1 inhibits Cdk2
hyperphosphorylation of the retinoblastoma protein (pRb), which
might synergize with cyclin DCdk4 phosphorylation of pRb.
Elucidation of the biochemical nature of the interaction between
p27Kip1 and Cdk4 will require additional studies. Our results
highlight the importance of cell-cycle gene function in the epithelial
cell compartment for the regulation of thymic lymphocyte growth
(12, 16).
It is noteworthy that p27Kip1 knockout mice are prone to devel-
oping T cell lymphomas, e.g., after exposure to the Moloney murine
leukemia virus or in conjunction with transgenic c-Myc expression
(26, 27). One intriguing idea is that inhibition of CDK activity in
nonneoplastic epithelial cells has tumor-suppressive action on
nearby lymphocytes harboring oncogene mutations just as it does
in normal thymocytes. There is growing interest in cell-
nonautonomous mechanisms of growth control and tumor sup-
pression such as through stromal–epithelial interactions and
through regulation of angiogenesis. Because they lack genetic
evidence of cellular autonomy, genes that display haploinsufficiency
in knockout mouse models may be more likely to suppress tumor
development through such unconventional mechanisms (28).
Methods
POMC–Cre Transgenics. A 5.5-kb segment of the POMC gene
promoter and 5 UTR was PCR-amplified from pHAL* (courtesy
of Malcolm Low, Oregon Health and Science University, Portland)
to include EcoRI and SalI ends and was ligated to pBS–Cre
(GIBCO) to include CreMT and poly(A) sequences. Transgenic
animals were created by pronuclear injection into CD-1 embryos.
Resultant progeny were screened by PCR using primers Cre1
(ACCTGATGGACATGTTCAGG) and Cre2 (CTACACCT-
GCGGTGCTAAC) for a 0.5-kb product and backcrossed 10
generations to 129S4. To verify the pattern of Cre expression,
POMC–Cre animals were bred to R26R reporter mice. Brain,
pituitary, and other organs were fixed in 4% paraformaldehyde and
stained with X-gal both in situ and in histologic sections.
p27loxP and p27stop Targeted p27Kip1 Mutants. The pKNFL target-
ing vector contains a 12.5-kb EcoRI fragment from a 129S4
genomic clone of p27Kip1. A neomycin (Neo)-selectable marker
flanked by FRT sequences and a single loxP sequence was inserted
into the BglII site 1.25 kb 3 of the stop codon. A second loxP
cassette was inserted into SacI 0.54 kb upstream of the initiation
codon. The p27NL mutation was introduced by homologous
recombination in AK7 mouse ES cells (also substrain 129S4) and
screened by PCR and Southern blots as described (1). Positive
clones were further screened by PCR for inclusion of the 5 loxP site
with primers K40 (TGGCAAACAGTCGGAGCGTAGG) and
Lox2 (AGCATACATTATACGAAGTTATATTAAGGGTT).
Chimeric mice were bred to 129S4 FlpeR mice to produce coiso-
genic animals without Neo (29). PCR-based genotyping was per-
formed with primers K53 (GGTATAATACGGAAAGT-
GACTCTAATGGCC) and K52 (TAGGGG AAATGGA-
TAGTAGATGTTAGGACC) for wild-type (p27) and p27L
alleles or with K53 and K57 (AGCGGCTCCCGGCCCGAGAC)
for the p27L allele.
p27stop mice were generated by using the pKSNL targeting
vector, which includes a Neo-selectable marker and three transcrip-
tion termination signals inserted into the BstBI site located 120 bp
upstream of the Start codon (30). ES cells were screened by
genomic Southern blots by using the 5 p27Kip1 probe as described
(see Fig. 7) (1). p27stop mouse genotyping was accomplished by
PCR with primers K55 (CGCCTGGCTCTGCT CCATTTGAC)
and K56 (GACACTCTCACGTTTGACATCTTCC) for wild-type
and p27S alleles or K55 and N5 (CTACCCGCTTCCATTGCT-
CAG) for the p27S allele. To demonstrate that the p27L and
p27S alleles produce the expected phenotypes, we induced germ-
line mutations by breeding both strains to 129S4 Mox2–Cre. The
resulting p27L and p27S alleles were bred to homozygosity in the
absence of Cre.
Growth, Fertility, and Pituitary Tumor Development. Weekly weights
were obtained from p27loxP mice (p27L/L) and p27stop mice
(p27S/S) and compared with wild-type littermates and with mice
with homozygous induced p27Kip1 mutations (p27/, p27L/L,
and p27S/S) until 15 weeks of age. Weekly weights were also
obtained from a second group of mice, designated as the ‘‘obser-
vation group’’ at the time of weaning, whose genotypes were either
p27L/L or p27S/S in combination with the POMC–Cre trans-
gene, and compared with littermates without Cre. Organ weights
were obtained from an additional 10 mice from each genotype at
6 weeks of age. Female fertility was assessed by recording the
production of offspring from a separate group of adult virgin
females of various genotypes (Table 1) paired with fertile males for
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an average of 3 months. Necropsies were performed in the obser-
vational cohort after development of morbid behavior or at 1 year
of age to determine causes of death and morbidity. Survival was
calculated with the R program (v.2.1; www.r-project.org) using the
survdiff function, pituitary weights were plotted with BOXPLOT, and
2 tests used CHISQ.TEST. Intact pituitaries were photographed in
situ on the skull base after excision of the brain and meninges. Pars
intermedia together with pars nervosa tissue was dissected free of
the pars distalis under a stereomicroscope, weighed, and then fixed
in 4% paraformaldehyde for histology, frozen for RNA and DNA,
or homogenized in RIPA buffer with protease and phosphatase
inhibitors for protein studies.
p27Kip1 Expression and CDK Activity. Western blots were stained with
rabbit anti-p27Kip1 antibody (1:2,000) and anti--tubulin monoclo-
nal antibody (1:10,000, T-0198, Sigma) followed by fluorescent goat
anti-mouse IgG–Alexa Fluor 680 (Molecular Probes) or goat
anti-rabbit IgG-IRDye800 (Rockland) and scanning on a Li-Cor
Odyssey. For qualitative assessment, horseradish peroxidase-
conjugated secondary antibodies were detected by ECL (Amer-
sham Pharmacia). p27Kip1 protein standards were generated from
admixtures of p27/ and p27/ tissue extracts. Protein loading
was normalized by adjustment to -tubulin staining in the same
lane. CDK activity using histone H1 substrate was determined after
immunoprecipitation with cyclin A or Cdk2 antibodies (Santa Cruz
Biotechnology) from 100 g of protein extract on Protein-A
Sepharose beads (Amersham Pharmacia) as described (31). RNA
from mouse tissues (n  4 for each genotype) was purified with
TRIzol (Invitrogen), and p27Kip1 quantitative RT-PCR was per-
formed by using SYBR green (Applied Biosystems) with primers
K25 (GCTGTTTACGTCTGGCGTCGA) and K66 (AGG-
AGAGCCAGGATGTCAGCG). Each sample was run in tripli-
cate and normalized to mouse ribosomal protein S16 (AGGAGC-
GATTTGCTGGTGTGGA and GCTACCAGGCCTTTG-
AGATGGA).
p27Kip1 Radiation Chimeras. p27Kip1 knockout mice, previously de-
scribed, were backcrossed (N15) to C57BL6J and then bred to
p27/ mice coisogenic to 129S4 to create p27/ F1 hybrids (1).
Control mice were F1 hybrids of 129S4 mice crossed to C57BL6J
mice or to C57 mice with the CD45.1 cell-surface polymorphism
(The Jackson Laboratory, stock catalog no. 2014, B6.SJL-Ptprca
Pep3bBoyJ). p27/ and p27/ F1 hybrid recipients (3.5 weeks
old, n  5 per group) were lethally irradiated (11 Gy, Linac) and
then transplanted with bone marrow pooled from either p27/ or
p27/ F1 hybrid donors (n  2–3) to create four groups as in Fig.
5A. Five weeks later mice were killed, and donor cell engraftment
of the blood, thymus, and splenocytes was assessed by flow cytom-
etry by using CD45.1 and CD45.2 antibodies (Pharmingen). Organs
were weighed and cell counts were obtained after suspension in
Iscove’s modified Dulbecco’s medium or RPMI medium 1640.
Splenic hematopoietic progenitor cells were quantified with colony-
forming assays for granulocyte-monocyte colony-forming cells
(CFC-GM), erythroid colony-forming cells (CFC-E), and erythroid
burst-forming units (BFU-E) as described (32). Plates were incu-
bated in 5% O2 plus 5% CO2, and colonies were scored on day 2
(CFU-E), days 5–6 (BFU-E), and day 7 (CFU-GM) by a researcher
blinded to the experimental group. The transplant procedure was
replicated to confirm the splenic colony-forming assays and thymus
flow cytometrykinase assays. FITC- or phycoerythrin-conjugated
rat monoclonal antibodies (CD4, CD8, CD3, TCR , Pharmin-
gen) were diluted 1:100 and incubated for 30 min with 105 (CD4 and
CD8) or 106 (CD3 and TCR ) thymocytes. Live cells were gated
by propidium iodide (10 gml) exclusion.
K5–Cdk4 Transgenics. The K5–Cdk4 transgene combines human
Cdk4 with the bovine K5 promoter (15). K5–Cdk4 transgenics were
backcrossed five generations to the SENCAR strain and then bred
for two generations to p27/ mice (C57BL6J) to generate
p27/;K5–Cdk4 compound mutants. Thymuses from young
adult animals (6–7 weeks) were minced and suspended in RPMI
medium 1640. Lymphocytes were separated from stromal material
by differential sedimentation. Four mice carrying various combi-
nations of p27/ and K5–Cdk4 were killed at 7 weeks of age for
histology to determine thymus size and for flow cytometry. An
additional four p27/;K5Cdk4 mice were assessed at 14–15
weeks.
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